Clinical trial
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity…
NCT05504252 · University Hospital, Akershus, Other · Active, not recruiting
Key facts
| NCT number | NCT05504252 |
|---|---|
| Title | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin |
| Official title | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin |
| Acronym | METIMMOX-2 |
| Lead sponsor | University Hospital, Akershus, Other |
| Collaborators | Oslo University Hospital St. Olavs Hospital |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Nivolumab, Oxaliplatin |
| Enrollment | 80 |
| Start date | Oct 5, 2022 |
| Primary completion | Jan 31, 2028 |
| Completion | Mar 1, 2028 |
| First posted | Aug 17, 2022 |
| Last update posted | Jan 7, 2026 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: